Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.
Charles River operates through three main segments:
- Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
- Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
- Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.
The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.
Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.
On April 13, 2023, Wheeler Bio, a contract development and manufacturing organization (CDMO), announced the closure of a $31 million Series A financing round, co-led by Charles River Laboratories (NYSE: CRL) and Echo. The funds will be used to complete a state-of-the-art CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with production expected to start in Q3 2023. Wheeler Bio's primary service, Portable CMC™, integrates development services to address client timelines and budgets, reducing risks associated with drug development. The company focuses on delivering small batch production for next-gen therapeutic proteins, positioning itself at the forefront of CMC drug development.
Charles River Laboratories International, Inc. (NYSE: CRL) will release its first-quarter 2023 financial results on May 11, before the market opens. A conference call to discuss the results is scheduled for 8:30 a.m. ET on the same day. Investors can listen to the live webcast through the Investor Relations section of the company's website, with a replay available afterward.
Charles River provides critical products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions worldwide. Their focus is on enhancing research and drug development processes to assist in the discovery and safe manufacture of new therapies.
Charles River Laboratories (NYSE: CRL) is showcasing its enhanced oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present 19 scientific posters and a spotlight presentation focusing on next-generation technologies in drug discovery and cell therapy development. Charles River has significantly contributed to cancer therapy advancements, being named co-inventors on 78 patents and supporting 16 clinical candidates, along with 11 FDA-approved therapies since 2018. Collaborative efforts with Cypre, Inc. and Kibur Medical are also highlighted, showcasing innovative approaches including the use of 3D hydrogel tumor models and implantable microdevices for enhanced drug-response tracking.
FAQ
What is the current stock price of Charles River Laboratories International (CRL)?
What is the market cap of Charles River Laboratories International (CRL)?
What services does Charles River Laboratories provide?
When was Charles River Laboratories founded?
Who are Charles River Laboratories' primary clients?
What is Charles River Laboratories' mission?
What is included in the Research Models & Services segment?
What does the Discovery & Safety Assessment segment offer?
What are some of the services provided under Manufacturing Support?
How does Charles River contribute to the healthcare industry?
What makes Charles River Laboratories a trusted partner in the life sciences industry?
What is the ticker symbol for Charles River Laboratories International, Inc.?
